Prerpints.org logo
Preprint
Article

Self-Completion Questionnaire on Sleep Evaluation in Patients Undergoing Oxaliplatin Therapy: An Observational Study

Altmetrics

Downloads

108

Views

70

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

10 January 2024

Posted:

11 January 2024

You are already at the latest version

Alerts
Abstract
Sleep is a fundamental human need: sleep disruption, in fact, causes an increase in the activity of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis, metabolic effects, changes in circadian rhythms and pro-inflammatory responses. Sci-entific literature is finally starting to pay attention to the central role of sleep-wake rhythm alterations for patients health. Oxaliplatin is used extensively for the treatment of gastrointestinal cancer and other malignancies, with increased frequency of use in recent years. This study aims to understand the effects of sleep-wake rhythm alterations on health and quality of life on cancer patients treated with oxaliplatin. Study has been conducted through the creation and distribution of questionnaires to patients to inves-tigate the potential alteration of the sleep-wake quality. Evaluating the influence of the collected variables on sleep quality, only liver and biliary tract and pancreas tumor lo-calization, in males, and previous difficulty sleeping, and anxiety, worries and stress, in females, resulted statistically significant. The results obtained may serve as foundation for designing awareness campaigns and updating of patients, healthcare personnel and caregivers, to improve health and quality of patients life.
Keywords: 
Subject: Medicine and Pharmacology  -   Pharmacology and Toxicology

1. Introduction

Sleep is a fundamental human need: a good quality sleep has a protective and restorative function that allows people to carry out their daily activities in an adequate way, ensuring physical, social, and emotional well-being. Prolonged wakefulness causes a wide spectrum of harmful physiological, psychological, and behavioral effects. Sleep alteration, in fact, causes an increase in the activity of the sympathetic nervous system and the hypothalamic-pituitary adrenal axis, metabolic effects, changes in circadian rhythms and pro-inflammatory responses. According to scientific research, people with cancer are more likely than the general population to experience sleep disruptions, which result in very fragmented sleep with a preference for the shallower, less restorative phases of sleep. The presence of high levels of noise, light, and multiple care activities in a hospital setting are environmental factors that can negatively impact the effectiveness and quality of sleep. These are intrinsic factors related to patients and their critical condition [1,2,3,4,5,6,7]. In accordance with other studies, the main contributors to the poor perception of sleep quality may include the number of patients in the room, the length of the stay, the presence and severity of pain, the patient’s attitude toward the hospital environment, the need to meet physiological needs, boredom, a feeling of dependence, worry about illness, and disrupted life patterns (such as missing work or being away from family, etc.) [8,9]. Further studies yet demonstrate that the subpar sleep during the stay continues even after dismissal [4,5,6,7]. Many and different are effects due to sleep-wake rhythm alterations. Increased stress reactivity, somatic pain, a decline in quality of life, emotional and mood disorders, cognitive deficiencies, memory, performance, and delirium are only a few of the short-term effects. Hypertension, dyslipidemia, cardio-vascular disease, issues with weight, metabolic syndrome, type 2 diabetes, and colorectal cancer are long-term effects [10,11,12]. Over 50% of cancer patients suffer from insomnia, nearly twice the estimated prevalence in the general population. Cancer and its treatments disturb sleep-wake functioning; however, there is little information available on the characteristics and consequences of sleep problems associated with cancer. The evaluation of the detrimental effects of a change in sleep-wake rhythm then is crucial in oncological pain [13]. Sleep disorders are prevalent in patients with advanced cancer, as indicated in paper by Innominato and colleagues [14]. Bernatchez and colleagues conducted a study in palliative cancer patients aimed at characterizing patients’ sleep-wake cycles using various circadian parameters, showing how the sleep-wake cycles are markedly disrupted in palliative cancer patients, especially, near the end of life [15]. Berger and colleagues also showed how fatigue is the most prevalent and distressing symptom experienced by patients receiving adjuvant chemotherapy for early stage breast cancer and higher fatigue levels have been related to sleep maintenance problems [16]. Oxaliplatin is a commonly used platinum-based chemotherapy drug for colorectal cancer and other malignancies, with increased frequency of use in recent years. A strong relationship between cancer and disrupted sleep-wake patterns has already been widely investigated in literature generally but very few evidences are currently present related to cancer patients treated with oxaliplatin. Yoshikawa and colleagues conducted a study to investigate quality of life and night-time sleep disturbance in colon cancer patients treated with oxaliplatin based chemotherapy [17]. Patients completed a questionnaire about chemotherapy-induced nausea and vomiting and sleep disturbance. Sleep disturbance was checked, and the relationship between sleep disturbance and nausea was analyzed leading to the result that nausea affects quality of life and night-time sleep of colon cancer patients. To conclude, even less evidences are present in literature related to sleep-wake rhythm alterations in cancer patients treated with oxaliplatin considering sex disaggregated data. Women experience sleep differently from men: each phase of a woman’s life, from childhood to menopause, increases the risk of sleep disturbance [18]. It is clearly agreed that sleep disorders represent both a cancer risk factor and a biological consequence of the activation of the immuno-inflammatory system induced by cancer itself: as consequence it is clear from literature that sleep disorders in cancer are then different among sexes and more common in women [19]. Further studies are evidently needed.

2. Materials and Methods

2.1. Patients and Inclusion Criteria

This was a descriptive retrospective study carried out at the Oncology Day Hospital Unit (COES) of the Molinette Hospital AOU Città della Salute e della Scienza in Turin (Italy) between May 2023 and May 2024. Inclusion criteria were as follows: age ≥18 years old, ability to understand and to agree to this study, Italian language and actively undergoing chemotherapy with oral or intravenous formulations of oxaliplatin. Exclusion criteria were as follow: age under 18 years old, assumptions of other chemotherapy agents. No data were collected regarding the start of therapy or the ongoing chemotherapy cycle.

2.2. Self-Completion Questionnaire

A self-completion questionnaire has been built to achieve the goal of our study. The first part of the questionnaire consisted of patient demographic data, including age, gender, highest level of education, marital status, tumor localization (lung, intestine, esophagus-gut, liver and biliary tract, pancreas and genitourinary tract), oral or intravenous oxaliplatin treatment, central venous catheter, stoma, concomitant therapies (corticosteroids, antiemetics, antipyretics, treatment of cardiovascular disease, insulin and oral hypoglycemic agents, antidepressant, treatment of thyroid disorders, antihistaminic and antipsychotic), concomitant pathology (cardiovascular diseases, diabetes, endocrine disorders, psychiatric disorders, arthritis/arthrosis, osteoporosis and rheumatic diseases, gastric disorders, intestinal diseases, genitourinary diseases, neurological diseases, respiratory disorders), parenteral nutrition, pain, consumption of drug to treat pain (antipyretics, non-steroidal anti-inflammatory drugs, opioids), previous difficulty sleeping (before starting any chemotherapy; yes/not), stress, worries and anxiety (yes/not) and insomnia and treatment for sleeping difficulties (phytotherapies, melatonin, chamomile, other drugs). The second part consists in the administration of a questionnaire relating to Sleep Hygiene [20], aimed to understanding and knowing patient main habits relating to their sleep, through the evaluation of 22 questions, considering how many times a week in the last month have been implemented. In order to calculate the Sleep Hygiene score, it is necessary to add the scores obtained. To interpret the results, it must be considered that higher scores indicate poorer sleep hygiene. The last part consists in the Pittsburgh Sleep Quality Index (PSQI) [21] that is the most used questionnaire to detect sleep disorders and the global quality of self-sleep - reported in clinical or non-clinical contexts, considering the month prior to completion, through 19 items that investigate seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications and daytime dysfunction. For this questionnaire we used the version validated in Italian in 2013 [22]: the authors state that the questionnaire validation maintains a high degree of coherence, that it correctly discriminates between patients suffering from pathologies that worsen the quality of sleep and by healthy participants belonging to the control group, both young and older, as well as confirming that the score used to differentiate the population with good sleep quality from the bad one (the threshold value indicating good sleep quality is 5, above this number sleep quality is worst) is also applicable to the Italian population. Therefore, in summary, we obtained single score from Sleep Hygiene questionnaire, PSQI score and PSQI greater or less than 5.
The questionnaire has been distributed to patients included in the study. In order to achieve the set objectives, a database was built in which the data were codified and collected.
Each patient provided written informed consent to fill out the questionnaire, and we received approval for this study from the Hospital Directors. Participation was voluntary, anonymous, and without compensation; therefore, each patient was free to choose whether to complete the questionnaire or not.
These data were routinely recorded during daily clinical practice as a quality assurance measure and to explore improvements in the quality of services; therefore, ethics committee approval was not required. Confidentiality was guaranteed in data collection, analysis, and dissemination phase, presenting the results in aggregate form.

2.3. Statistical Analysis

All the variables were tested for normality with the Shapiro–Wilk test. The correspondence of each parameter was evaluated with a normal or non-normal distribution, through the Kolmogorov–Smirnov test. Quantitative variables were described via median and interquartile range (IQR, quartile 1; quartile 3) if the variables were not normally distributed. Qualitative variables were described via frequencies and percentages. The data were analyses considering separately male and female patients. Kruskal–Wallis and Mann–Whitney tests were used to evaluate the influence of variables on Sleep Hygiene score, PSQI score and PSQI cutoffs (lower than 5 and higher than 5) considering the level of statistical significance (P < 0.05).
Any predictive power of all the considered variables was finally evaluated through univariate and multivariate linear (for sleep hygiene score and PSQI) and logistic (considering PSQI above than 5) regression analyses. Factors [β, β coefficient for linear model; Exp(B), exponentiation of the B coefficient for logistic model; confidence interval (CI) at 95% for the parameter B, for linear model, or Exp(B) for logistic model] with a P value less than 0.2 in univariate analysis were included in the multivariate analysis (P < 0.05).
All the tests were performed with IBM SPSS statistics 25.0 for Windows (SPSS Inc., Chicago, Illinois, USA).

3. Results

3.1. Study Population

A total of 144 patients were enrolled, the 42.4% were females and the 57.6 were males; their demographical characteristics, Sleep Hygiene score and PSQI statistic results are shown in Table 1.
The distribution of their social, clinical and therapeutic characteristics is resumed in Table 2.

3.2. Influence of Sex on Sleep Quality

Evaluating the influnce of sex on sleep quality, we observed a statistically significant differences regarding sleep hygiene score, with a female median value of 1.68 (IQR 1.32-2) versus the 1.36 (IQR 1.14-1.82) for males (Figure 1).
A borderline influence has been also observed evaluating the PSQI (p=0.057), with a females median value of 6 (IQR 4-10) and a median value form males of 5 (IQR 4-8). Instead, regarding the PSQI score below or above 5, a statistically significant difference has been observed comparing females and males (p=0.013; Figure 2).
Eventaully, evaluating the previously sleeping difficulties, we observed statistically significative different distribution between sexes (p=0.017; Figure 3).
Evaluating men and women separately, we reported that in females, the declared previous difficulty sleeping, thus before the starting of chemotherapy, negatively influenced PSQI, whit a median value of 10 (IQR 7-13) versus the 6 (IQR 3.75-9) of those without previous difficulty (p=0.004)(Figure 4).
Again, in female patients, reported stress, worries and anxiety influenced sleep hygiene score (p=0.048) whti a score of 1.68 (IQR 1.31-1.95) versus 2.2 (IQR 1.9-2.57) in those whitout these sybntomps (Figure 5).

3.3. Regression Analyses

Considering the sleep hygiene score, no variables were riteined in the linear regression model. Evaluating the PSQI, we observed a predictive role of phytotherapic use (p=0.04; β=-0.490; IC95% -14.987 and -0.413); in addition a borderline role resulted consideing sex variable (p=0.053; β=-0.457; IC95% -7.121 and 0.055).
Carring out a logistic model to evaluate the predictive role of collected variables on PSQI score above than 5, we reported that only sex has been retained with a p=0.001 (Exp(B)=0.139; IC95% 0.042 and 0.462)

4. Discussion

From the analysis of the collected data, and in accordance with the literature [17,22,23,24,25,26,27,28], it was possible to identify the presence of sleep disorders in patients undergoing oncological treatment, in our study oxaliplatin based therapy, who participated in completing the questionnaire. Thus, we can see, through the results of the PSQI questionnaire, that more than the 77% of the participants have a poor quality of sleep, and this is observed above all in females. There are studies in the literature that use the same questionnaire to investigate sleep quality in cancer patients, whether undergoing treatment or not. In a 2020 observational study, despite the limited sample of patients examined (92 participants), results similar to our research were found: 57.6% showed a PSQI score > 5 and an average of 6, 57 which indicate poor sleep quality [29]. Even in a 2022 meta-analysis sleeping disorders were found in 64% of patients, using the PSQI questionnaire [30]. And again, in a 2022 review, the authors compare the mean PSQI scores before, during and after oncological treatment with the following results: 7.11 – 8.31 – 7.10 (all statistically significant for p < 0.001), thus demonstrating that patients undergoing treatment suffer more from sleep alterations with a lower quality of sleep [22]. Considering our observed sex differences, studies in literature report that sleep disorders within the general population are more frequent in females [31]. Regarding cancer patients undergoing oncological treatment, many studies showed that female sex is significantly correlated with lower sleep quality [24,30,32,33,34,35]. Within a 2022 meta-analysis study the association between sleep disorders and female sex was found to be statically significant, mainly finding the less possibility of having social support and the higher exposition and affection by pathologies such as anxiety and depression [30]. Conversely, in a 2021 study in which the sleep quality of patients was investigated through the compilation of numerous validated questionnaires, the correlation between PSQI scores and female gender resulted not statistically significant [36]. We observed a trend towards better sleep quality in women, with a higher median value of the sleep quality index. But, in our population, there are approximately twice as many men with a PSQI below than 5, thus with a good sleep quality, compared to female patients; in addition, linear and regression analyses on PSQI and PSQI above than 5 showed that male sex has a predictive role for a better sleep.
In addition to investigating the quality of sleep during the treatment, the patients were asked if they had suffered from sleep disorders or insomnia before the start of oncological therapy: some studies in the literature show an investigation into the quality of the patients sleep, through the compilation of the PSQI questionnaire in at least two different periods, i.e., before and during treatment, both to evaluate the effect of therapy and to take into consideration previous problems [22,37]. From the results obtained, there is a statistically significant correlation between previous difficulty sleeping and the quality of sleep during oncological treatment (p < 0.001) in 20.9% of participants, showing an average score higher than those who report absence of sleeping disorders before treatment. This data indicates that those with previous problems have a higher risk of a worst sleep quality during treatment. In our study, in female patients who declared previous difficulty sleeping, a higher PSQI and thus a worst quality sleep resulted. Moreover, compared to the male population, over twice as many women reported having difficulty sleeping even before beginning oxaliplatin medication.
In our study, age does not represent a statistically significant variable correlated to the disorders of the sleep quality, contrary to what is reported in the literature, in which advanced age is associated with a significant worsening of the sleep-wake rhythm during oncological therapy, in particular considering intravenous chemotherapy and patients over 75 years old, due to the greater presence of comorbidities [17,26,33,34,38]. In a 2020 review study, however, age significantly affects poor sleep quality in both older and younger patients [24]. Conversely, in other works it emerges that older patients experience sleep disturbances to a lesser or similar extent compared to young people [39], but the greatest prevalence of disorders is found in the age group between 40 and 49 years old [30].
Both research and scientific evidence showed that there is no statistically significant correlation between PSQI score and marital status [36].
In the data collection of our study, as well as in the literature, the various primary oncological pathologies of the selected sample were examined [22,33,38,40,41]. In the selected scientific studies, it is claimed that based on the type of tumor a different load of symptoms depends, as well as a variation in the quality of sleep, in particular in patients with lung cancer due to the presence of respiratory problems [40,42,43]. Unfortunately, the great variety of oncological pathologies and the relatively small sample of our study did not allow us to carry out an effective statistical analysis.
The associations between sleep alterations, type of treatment and chemotherapy drugs do not provide statistically significant data. The relatively small sample size may also have influenced this result, especially for some variables which have lower frequencies. In the literature, some studies agree with the same result found [29,42], while within a 2022 meta-analysis, the authors argue that there are higher levels of sleep disorders in patients subjected to a mixed treatment, and this is also given by treatment-related toxicities [30].
According to the literature, a greater presence of comorbidities resulted correlated with an equally deterioration of the sleep-wake rhythm [38]: in particular, anxiety and depression are relevant and have an impact on sleep [36,44,45,46,47,48]. We observed that self-reported stress, worries and anxiety negatively influenced the sleep quality score, with a better quality of sleep in those who do not experience these symptoms.
In our cohort we have not observed significant influences of the use of concomitant drugs, even used to treat insomnia, on the quality of sleep. Conversely, in literature, corticosteroids, antiemetics and antidepressants are reported as drugs that worsen sleep quality, particularly by altering sleep maintenance and latency [36]. Another drug category that could affects the sleep-wake rhythm is represented by opioids, since they cause nocturnal breathing problems and a state of sedation during the day, as well as anxiety and insomnia [36,49,50]. According to some evidence, however, these medicines could also have positive effects by improving the quality of sleep, for example the regular administration of low quantities of morphine can reduce respiratory problems [51].
Contrary to what we observed, the evidence present in the literature stated that sleep quality and pain are negatively correlated [26,34,50], such as that sleep disorders symptoms could cause pain threshold reduction [52]. Even according to a 2020 review, pain and sleep are physiological mechanisms connected to each other, in fact severe pain is associated with a worse quality of sleep [24].
Eventually, we observed the PSQI predictive role phytotherapy, therefore hypothesizing that it can have positive effects on the quality of sleep. The general population finds non-pharmacological therapies especially appealing since they are thought to have no negative side effects [53]. Among the most popular complementary and alternative medicine choices are herbal medicines and medicinal herbs [54,55,56]. The general public especially welcomes them for sleep disorders. Researchers worldwide have assessed and shown the greatest interest in the following plants for sleep disturbances: Valeriana officinalis), Lavandula angustifolia, Humulus lupulus, Matricaria chamomilla, Crataegus monogyna, Hypericum perforatum and Rosmarinus officinalis [57].
The importance of sleep education in cancer patients during chemotherapy periods to improve the quality of sleep has been already highlighted [58]. Within this research, a score was obtained through the relevant questionnaire used to quantify the patient sleep hygiene, with a median PSQI of 6 (IQR 4-9), which remains almost unchanged in males; in female patients instead, the data get worse with a medina value of 5 (IQR 4-8).
Good quality sleep can improve energy, quality of life and coping, refers to the attitudes and behaviors to maintain emotional well-being and to adjust the diagnosis-caused stress, in cancer patients. The literature underline the importance of the nursing figure and of the knowledge of phases of sleep, its disorders and the main factors that can cause them [59]; promotion and treatment interventions can be implemented, also through the integration of a specific sleep assessment into ordinary care in a multidisciplinary approach [24,34]. According to a 2022 review, it is important for the nurse to have an active role in this process, collaborating with the patients themselves and their families to choose the types of interventions to counteract sleep-wake rhythm disorders and to carry out the related monitoring [60]. The role of the nurse could be upgraded, both through research, conducting more specific studies and with larger samples that can better reflect the sleep quality of cancer patients undergoing systemic treatment, and by raising awareness among staff to introduce assessments into daily clinical practice.
This study has limitations. The first of all is the data collection method: using a “self-reported” questionnaire filled out freely by the patient, without medical consultation; for this reason, some information may be inaccurate or incomplete. Furthermore, no data were collected regarding the start of therapy or the ongoing chemotherapy cycle; the patient was asked to complete the questionnaire during the treatment period, without considering the time that had passed since its start and the number of sessions already carried out. A more precise study could be produced by examining a predefined sample of patients and administering the questionnaire to them more than once at predefined times during therapy, to evaluate the changes in sleep quality. In addition, in this research there are no variables that define the staging of the tumor and the presence of metastases: both are aspects which, according to evidence, can influence the quality of sleep [26,34]. Evaluating to two other studies, however, it has been demonstrated that there is no statistically significant association between PSQI score and tumor staging, while an association is found between alteration of the sleep-wake rhythm and metastases, in particular visceral and bone ones [36,42].
An aspect that was not investigated in this research, but considered in other studies, was the influence of physical activity on sleep in cancer patients. In a longitudinal study it was highlighted how, patients who do not perform physical activity, presented higher levels of fatigue in the morning, sleep disturbances and lower levels of energy in the morning and evening compared to those who carry it out [61]. Moreover, in a 2019 meta-analysis the importance for cancer patients of maintaining physical activity and exercises practice, especially the aerobic type, could improves their quality of sleep [62].

5. Conclusions

In conclusion, from this research it emerges that patients undergoing oncological therapies present overall a poor sleep quality, and that these disorders are associated with anxiety, worries, depression and previous difficulty sleeping, in female sex, and with tumor localization, in males.

Author Contributions

Conceptualization, M.V.M. and F.M.D.; methodology, S.S. and T.A.; software, S.A.; validation, G.A. and F.C.; formal analysis, S.A.; investigation, F.M.D.; resources, S.S. and T.A.; data curation, F.M.D; writing—original draft preparation, S.A. and S.D.F; writing—review and editing, M.V.M.; supervision, M.V.M and S.D.F..; project administration, S.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Ethics Committee of Comitato Etico Territoriale Interaziendale AOU Città della Salute e della Scienza di Torino (protocol code 889.866, 02/10/2023).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Beltrami, F.G.; Nguyen, X.L.; Pichereau, C.; Maury, E.; Fleury, B.; Fagondes, S. Sleep in the intensive care unit. J Bras Pneumol 2015, 41, 539–546. [Google Scholar] [CrossRef] [PubMed]
  2. Manian, F.A.; Manian, C.J. Sleep quality in adult hospitalized patients with infection: an observational study. Am J Med Sci 2015, 349, 56–60. [Google Scholar] [CrossRef] [PubMed]
  3. Zhang, L.; Sha, Y.S.; Kong, Q.Q.; Woo, J.A.; Miller, A.R.; Li, H.W.; Zhou, L.X.; Zhou, Y.; Wang, C.L. Factors that affect sleep quality: perceptions made by patients in the intensive care unit after thoracic surgery. Support Care Cancer 2013, 21, 2091–2096. [Google Scholar] [CrossRef] [PubMed]
  4. Nesbitt, A.D.; Leschziner, G.D.; Peatfield, R.C. Headache, drugs and sleep. Cephalalgia 2014, 34, 756–766. [Google Scholar] [CrossRef] [PubMed]
  5. Nesbitt, A.D. Delayed sleep-wake phase disorder. J Thorac Dis 2018, 10, S103–S111. [Google Scholar] [CrossRef]
  6. Nesbitt, L.; Goode, D. Nurses perceptions of sleep in the intensive care unit environment: a literature review. Intensive Crit Care Nurs 2014, 30, 231–235. [Google Scholar] [CrossRef]
  7. Nesbitt, A.D.; Dijk, D.J. Out of synch with society: an update on delayed sleep phase disorder. Curr Opin Pulm Med 2014, 20, 581–587. [Google Scholar] [CrossRef]
  8. Young, J.S.; Bourgeois, J.A.; Hilty, D.M.; Hardin, K.A. Sleep in hospitalized medical patients, part 2: behavioral and pharmacological management of sleep disturbances. J Hosp Med 2009, 4, 50–59. [Google Scholar] [CrossRef]
  9. Young, J.S.; Bourgeois, J.A.; Hilty, D.M.; Hardin, K.A. Sleep in hospitalized medical patients, part 1: factors affecting sleep. J Hosp Med 2008, 3, 473–482. [Google Scholar] [CrossRef]
  10. Stewart, N.H.; Arora, V.M. Sleep in Hospitalized Older Adults. Sleep Med Clin 2022, 17, 223–232. [Google Scholar] [CrossRef]
  11. Stewart, N.H.; Arora, V.M. Sleep in Hospitalized Older Adults. Sleep Med Clin 2018, 13, 127–135. [Google Scholar] [CrossRef]
  12. Medic, G.; Wille, M.; Hemels, M.E. Short- and long-term health consequences of sleep disruption. Nat Sci Sleep 2017, 9, 151–161. [Google Scholar] [CrossRef]
  13. Gonella, S. [Sleep-wake cycle in chemotherapy patients: a retrospective study]. Minerva Med 2010, 101, 135–147. [Google Scholar]
  14. Innominato, P.F.; Spiegel, D.; Ulusakarya, A.; Giacchetti, S.; Bjarnason, G.A.; Lévi, F.; Palesh, O. Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer. Sleep Med 2015, 16, 391–398. [Google Scholar] [CrossRef]
  15. Bernatchez, M.S.; Savard, J.; Ivers, H. Disruptions in sleep-wake cycles in community-dwelling cancer patients receiving palliative care and their correlates. Chronobiol Int 2018, 35, 49–62. [Google Scholar] [CrossRef]
  16. Berger, A.M.; Farr, L.A.; Kuhn, B.R.; Fischer, P.; Agrawal, S. Values of sleep/wake, activity/rest, circadian rhythms, and fatigue prior to adjuvant breast cancer chemotherapy. J Pain Symptom Manage 2007, 33, 398–409. [Google Scholar] [CrossRef]
  17. Yoshikawa, K.; Higashijima, J.; Okitsu, H.; Miyake, H.; Yagi, T.; Miura, M.; Bando, Y.; Ando, T.; Hotchi, M.; Ishikawa, M.; et al. Effects of chemotherapy on quality of life and night-time sleep of colon cancer patients. J Med Invest 2020, 67, 338–342. [Google Scholar] [CrossRef] [PubMed]
  18. Pengo, M.F.; Won, C.H.; Bourjeily, G. Sleep in Women Across the Life Span. Chest 2018, 154, 196–206. [Google Scholar] [CrossRef] [PubMed]
  19. Scher, N.; Guetta, L.; Draghi, C.; Yahiaoui, S.; Terzioglu, M.; Butaye, E.; Henriques, K.; Alavoine, M.; Elharar, A.; Guetta, A.; et al. Sleep Disorders and Quality of Life in Patients With Cancer: Prospective Observational Study of the Rafael Institute. JMIR Form Res 2022, 6, e37371. [Google Scholar] [CrossRef]
  20. Adan, A.; Fabbri, M.; Natale, V.; Prat, G. Sleep Beliefs Scale (SBS) and circadian typology. J Sleep Res 2006, 15, 125–132. [Google Scholar] [CrossRef] [PubMed]
  21. Curcio, G.; Tempesta, D.; Scarlata, S.; Marzano, C.; Moroni, F.; Rossini, P.M.; Ferrara, M.; De Gennaro, L. Validity of the Italian version of the Pittsburgh Sleep Quality Index (PSQI). Neurol Sci 2013, 34, 511–519. [Google Scholar] [CrossRef]
  22. Divani, A.; Heidari, M.E.; Ghavampour, N.; Parouhan, A.; Ahmadi, S.; Narimani Charan, O.; Shahsavari, H. Effect of cancer treatment on sleep quality in cancer patients: A systematic review and meta-analysis of Pittsburgh Sleep Quality Index. Support Care Cancer 2022, 30, 4687–4697. [Google Scholar] [CrossRef]
  23. Chen, M.L.; Yu, C.T.; Yang, C.H. Sleep disturbances and quality of life in lung cancer patients undergoing chemotherapy. Lung Cancer 2008, 62, 391–400. [Google Scholar] [CrossRef]
  24. Souza, R.C.D.S.; Dos Santos, M.R.; das Chagas Valota, I.A.; Sousa, C.S.; Costa Calache, A.L.S. Factors associated with sleep quality during chemotherapy: An integrative review. Nurs Open 2020, 7, 1274–1284. [Google Scholar] [CrossRef]
  25. Romito, F.; Cormio, C.; De Padova, S.; Lorusso, V.; Berio, M.A.; Fimiani, F.; Piattelli, A.; Palazzo, S.; Abram, G.; Dudine, L.; et al. Patients attitudes towards sleep disturbances during chemotherapy. Eur J Cancer Care (Engl) 2014, 23, 385–393. [Google Scholar] [CrossRef]
  26. Nzwalo, I.; Aboim, M.A.; Joaquim, N.; Marreiros, A.; Nzwalo, H. Systematic Review of the Prevalence, Predictors, and Treatment of Insomnia in Palliative Care. Am J Hosp Palliat Care 2020, 37, 957–969. [Google Scholar] [CrossRef]
  27. Strollo, S.E.; Fallon, E.A.; Gapstur, S.M.; Smith, T.G. Cancer-related problems, sleep quality, and sleep disturbance among long-term cancer survivors at 9-years post diagnosis. Sleep Med 2020, 65, 177–185. [Google Scholar] [CrossRef] [PubMed]
  28. Innominato, P.F.; Giacchetti, S.; Bjarnason, G.A.; Focan, C.; Garufi, C.; Coudert, B.; Iacobelli, S.; Tampellini, M.; Durando, X.; Mormont, M.C.; et al. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer 2012, 131, 2684–2692. [Google Scholar] [CrossRef] [PubMed]
  29. Pai, A.; Sivanandh, B.; Udupa, K. Quality of Sleep in Patients with Cancer: A Cross-sectional Observational Study. Indian J Palliat Care 2020, 26, 9–12. [Google Scholar] [CrossRef]
  30. Al Maqbali, M.; Al Sinani, M.; Alsayed, A.; Gleason, A.M. Prevalence of Sleep Disturbance in Patients With Cancer: A Systematic Review and Meta-Analysis. Clin Nurs Res 2022, 31, 1107–1123. [Google Scholar] [CrossRef] [PubMed]
  31. Smagula, S.F.; Stone, K.L.; Fabio, A.; Cauley, J.A. Risk factors for sleep disturbances in older adults: Evidence from prospective studies. Sleep Med Rev 2016, 25, 21–30. [Google Scholar] [CrossRef]
  32. Lin, Y.; Bailey, D.E.; Docherty, S.L.; Porter, L.S.; Cooper, B.A.; Paul, S.M.; Hammer, M.J.; Conley, Y.P.; Levine, J.D.; Miaskowski, C. Distinct Sleep Disturbance Profiles in Patients With Gastrointestinal Cancers Receiving Chemotherapy. Cancer Nurs 2022, 45, E417–E427. [Google Scholar] [CrossRef] [PubMed]
  33. Induru, R.R.; Walsh, D. Cancer-related insomnia. Am J Hosp Palliat Care 2014, 31, 777–785. [Google Scholar] [CrossRef]
  34. Endeshaw, D.; Biresaw, H.; Asefa, T.; Yesuf, N.N.; Yohannes, S. Sleep Quality and Associated Factors Among Adult Cancer Patients Under Treatment at Oncology Units in Amhara Region, Ethiopia. Nat Sci Sleep 2022, 14, 1049–1062. [Google Scholar] [CrossRef]
  35. Siefert, M.L.; Hong, F.; Valcarce, B.; Berry, D.L. Patient and clinician communication of self-reported insomnia during ambulatory cancer care clinic visits. Cancer Nurs 2014, 37, E51–59. [Google Scholar] [CrossRef] [PubMed]
  36. Strik, H.; Cassel, W.; Teepker, M.; Schulte, T.; Riera-Knorrenschild, J.; Koehler, U.; Seifart, U. Why Do Our Cancer Patients Sleep So Badly? Sleep Disorders in Cancer Patients: A Frequent Symptom with Multiple Causes. Oncol Res Treat 2021, 44, 469–475. [Google Scholar] [CrossRef]
  37. Fakih, R.; Rahal, M.; Hilal, L.; Hamieh, L.; Dany, M.; Karam, S.; Shehab, L.; El Saghir, N.S.; Tfayli, A.; Salem, Z.; et al. Prevalence and Severity of Sleep Disturbances among Patients with Early Breast Cancer. Indian J Palliat Care 2018, 24, 35–38. [Google Scholar] [CrossRef]
  38. Palesh, O.; Peppone, L.; Innominato, P.F.; Janelsins, M.; Jeong, M.; Sprod, L.; Savard, J.; Rotatori, M.; Kesler, S.; Telli, M.; et al. Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Nat Sci Sleep 2012, 4, 151–162. [Google Scholar] [CrossRef] [PubMed]
  39. Bischel, L.E.; Ritchie, C.; Kober, K.M.; Paul, S.M.; Cooper, B.A.; Chen, L.M.; Levine, J.D.; Hammer, M.; Wright, F.; Miaskowski, C. Age differences in fatigue, decrements in energy, and sleep disturbance in oncology patients receiving chemotherapy. Eur J Oncol Nurs 2016, 23, 115–123. [Google Scholar] [CrossRef]
  40. Chen, D.; Yin, Z.; Fang, B. Measurements and status of sleep quality in patients with cancers. Support Care Cancer 2018, 26, 405–414. [Google Scholar] [CrossRef]
  41. Kiss, I.; Kuhn, M.; Hrusak, K.; Buchler, B.; Boublikova, L.; Buchler, T. Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. Front Oncol 2022, 12, 946307. [Google Scholar] [CrossRef] [PubMed]
  42. Akman, T.; Yavuzsen, T.; Sevgen, Z.; Ellidokuz, H.; Yilmaz, A.U. Evaluation of sleep disorders in cancer patients based on Pittsburgh Sleep Quality Index. Eur J Cancer Care (Engl) 2015, 24, 553–559. [Google Scholar] [CrossRef]
  43. Chung, K.F.; Lee, C.T.; Yeung, W.F.; Chan, M.S.; Chung, E.W.; Lin, W.L. Sleep hygiene education as a treatment of insomnia: a systematic review and meta-analysis. Fam Pract 2018, 35, 365–375. [Google Scholar] [CrossRef]
  44. Palesh, O.G.; Roscoe, J.A.; Mustian, K.M.; Roth, T.; Savard, J.; Ancoli-Israel, S.; Heckler, C.; Purnell, J.Q.; Janelsins, M.C.; Morrow, G.R. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol 2010, 28, 292–298. [Google Scholar] [CrossRef]
  45. Inhestern, L.; Beierlein, V.; Bultmann, J.C.; Möller, B.; Romer, G.; Koch, U.; Bergelt, C. Anxiety and depression in working-age cancer survivors: a register-based study. BMC Cancer 2017, 17, 347. [Google Scholar] [CrossRef] [PubMed]
  46. Walker, W.H.; Borniger, J.C. Molecular Mechanisms of Cancer-Induced Sleep Disruption. Int J Mol Sci 2019, 20. [Google Scholar] [CrossRef]
  47. Carney, C.E.; Edinger, J.D.; Kuchibhatla, M.; Lachowski, A.M.; Bogouslavsky, O.; Krystal, A.D.; Shapiro, C.M. Cognitive Behavioral Insomnia Therapy for Those With Insomnia and Depression: A Randomized Controlled Clinical Trial. Sleep 2017, 40. [Google Scholar] [CrossRef] [PubMed]
  48. Kalmbach, D.A.; Cheng, P.; Arnedt, J.T.; Anderson, J.R.; Roth, T.; Fellman-Couture, C.; Williams, R.A.; Drake, C.L. Treating insomnia improves depression, maladaptive thinking, and hyperarousal in postmenopausal women: comparing cognitive-behavioral therapy for insomnia (CBTI), sleep restriction therapy, and sleep hygiene education. Sleep Med 2019, 55, 124–134. [Google Scholar] [CrossRef]
  49. Mansano-Schlosser, T.C.; Ceolim, M.F. Factors associated with sleep quality in the elderly receiving chemotherapy. Rev Lat Am Enfermagem 2012, 20, 1100–1108. [Google Scholar] [CrossRef]
  50. Dahiya, S.; Ahluwalia, M.S.; Walia, H.K. Sleep disturbances in cancer patients: underrecognized and undertreated. Cleve Clin J Med 2013, 80, 722–732. [Google Scholar] [CrossRef]
  51. Mercadante, S.; Adile, C.; Ferrera, P.; Masedu, F.; Valenti, M.; Aielli, F. Sleep disturbances in advanced cancer patients admitted to a supportive/palliative care unit. Support Care Cancer 2017, 25, 1301–1306. [Google Scholar] [CrossRef] [PubMed]
  52. Wu, I.H.C.; Balachandran, D.D.; Faiz, S.A.; Bashoura, L.; Escalante, C.P.; Manzullo, E.F. Characteristics of Cancer-Related Fatigue and Concomitant Sleep Disturbance in Cancer Patients. J Pain Symptom Manage 2022, 63, e1–e8. [Google Scholar] [CrossRef] [PubMed]
  53. Panossian, A. Challenges in phytotherapy research. Front Pharmacol 2023, 14, 1199516. [Google Scholar] [CrossRef] [PubMed]
  54. Barnes, J. Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part I. Regulation and quality. Br J Clin Pharmacol 2003, 55, 226–233. [Google Scholar] [CrossRef] [PubMed]
  55. Seyed Hashemi, M.; Namiranian, N.; Tavahen, H.; Dehghanpour, A.; Rad, M.H.; Jam-Ashkezari, S.; Emtiazy, M.; Hashempur, M.H. Efficacy of Pomegranate Seed Powder on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes: A Prospective Randomized Double-Blind Placebo-Controlled Clinical Trial. Complement Med Res 2021, 28, 226–233. [Google Scholar] [CrossRef] [PubMed]
  56. Nayebi, N.; Esteghamati, A.; Meysamie, A.; Khalili, N.; Kamalinejad, M.; Emtiazy, M.; Hashempur, M.H. The effects of a Melissa officinalis L. based product on metabolic parameters in patients with type 2 diabetes mellitus: A randomized double-blinded controlled clinical trial. J Complement Integr Med 2019, 16. [Google Scholar] [CrossRef]
  57. Guadagna, S.; Barattini, D.F.; Rosu, S.; Ferini-Strambi, L. Plant Extracts for Sleep Disturbances: A Systematic Review. Evid Based Complement Alternat Med 2020, 2020, 3792390. [Google Scholar] [CrossRef]
  58. Alem, L.; Ansari, H.; Hajigholami, A. Evaluation of Sleep Training Effectiveness on the Quality of Sleep in Cancer Patients during Chemotherapy. Adv Biomed Res 2021, 10, 11. [Google Scholar] [CrossRef]
  59. Vena, C.; Parker, K.; Cunningham, M.; Clark, J.; McMillan, S. Sleep-wake disturbances in people with cancer part I: an overview of sleep, sleep regulation, and effects of disease and treatment. Oncol Nurs Forum 2004, 31, 735–746. [Google Scholar] [CrossRef]
  60. Matthews, E.E.; Wang, S.Y. Cancer-Related Sleep Wake Disturbances. Semin Oncol Nurs 2022, 38, 151253. [Google Scholar] [CrossRef]
  61. Moy, S.; Kober, K.M.; Viele, C.; Paul, S.M.; Hammer, M.; Melisko, M.; Wright, F.; Conley, Y.P.; Levine, J.D.; Miaskowski, C. Level of Exercise Influences the Severity of Fatigue, Energy Levels, and Sleep Disturbance in Oncology Outpatients Receiving Chemotherapy. Cancer Nurs 2022, 45, 3–11. [Google Scholar] [CrossRef] [PubMed]
  62. Fang, Y.Y.; Hung, C.T.; Chan, J.C.; Huang, S.M.; Lee, Y.H. Meta-analysis: Exercise intervention for sleep problems in cancer patients. Eur J Cancer Care (Engl) 2019, 28, e13131. [Google Scholar] [CrossRef] [PubMed]
Preprints 96018 g001
Figure 1. Influence of sex on sleep hygiene score (p=0.019) in patients undergoing oxaliplatin chemotherapy, obtained with Mann-Whitney test. Box plot of sleep hygiene score distribution in females and males patients; boxes and black lines in boxes represent respectively interquartile ranges (IQR) and median values; open dots and stars represent outlier values. Median values (horizontal line), IQR (bars), patient values (black square), highest and lowest value (whiskers) and p value are shown.
Figure 1. Influence of sex on sleep hygiene score (p=0.019) in patients undergoing oxaliplatin chemotherapy, obtained with Mann-Whitney test. Box plot of sleep hygiene score distribution in females and males patients; boxes and black lines in boxes represent respectively interquartile ranges (IQR) and median values; open dots and stars represent outlier values. Median values (horizontal line), IQR (bars), patient values (black square), highest and lowest value (whiskers) and p value are shown.
Preprints 96018 g001
Preprints 96018 g002
Figure 2. Distribution of Pittsburgh Sleep Quality Index (PSQI) in female and in male patients undergoing oxaliplatin chemotherapy. Number and percentage of patients in each variable and p value are shown.
Figure 2. Distribution of Pittsburgh Sleep Quality Index (PSQI) in female and in male patients undergoing oxaliplatin chemotherapy. Number and percentage of patients in each variable and p value are shown.
Preprints 96018 g002
Preprints 96018 g003
Figure 3. Distribution of previous difficulty sleeping in female and in male patients undergoing oxaliplatin chemotherapy. Number and percentage of patients in each variable and p value are shown.
Figure 3. Distribution of previous difficulty sleeping in female and in male patients undergoing oxaliplatin chemotherapy. Number and percentage of patients in each variable and p value are shown.
Preprints 96018 g003
Preprints 96018 g004
Figure 4. Influence of difficulty sleeping before the starting of chemotherapy on Pittsburgh Sleep Quality Index (p=0.004) in female patients, obtained with Mann-Whitney test. Box plot of sleep Pittsburgh Sleep Quality Index distribution in female patients; boxes and black lines in boxes represent respectively interquartile ranges (IQR) and median values; open dots and stars represent outlier values. Median values (horizontal line), IQR (bars), patient values (black square), highest and lowest value (whiskers) and p value are shown.
Figure 4. Influence of difficulty sleeping before the starting of chemotherapy on Pittsburgh Sleep Quality Index (p=0.004) in female patients, obtained with Mann-Whitney test. Box plot of sleep Pittsburgh Sleep Quality Index distribution in female patients; boxes and black lines in boxes represent respectively interquartile ranges (IQR) and median values; open dots and stars represent outlier values. Median values (horizontal line), IQR (bars), patient values (black square), highest and lowest value (whiskers) and p value are shown.
Preprints 96018 g004
Preprints 96018 g005
Figure 5. Influence of stress, worries and anxiety on sleep hygiene score (p=0.048) in female patients, obtained with Mann-Whitney test. Box plot of sleep hygiene score distribution in female patients; boxes and black lines in boxes represent respectively interquartile ranges (IQR) and median values; open dots and stars represent outlier values. Median values (horizontal line), IQR (bars), patient values (black square), highest and lowest value (whiskers) and p value are shown.
Figure 5. Influence of stress, worries and anxiety on sleep hygiene score (p=0.048) in female patients, obtained with Mann-Whitney test. Box plot of sleep hygiene score distribution in female patients; boxes and black lines in boxes represent respectively interquartile ranges (IQR) and median values; open dots and stars represent outlier values. Median values (horizontal line), IQR (bars), patient values (black square), highest and lowest value (whiskers) and p value are shown.
Preprints 96018 g005
Table 1. Demographical characteristics, Sleep Hygiene score and PSQI statistic results.
Table 1. Demographical characteristics, Sleep Hygiene score and PSQI statistic results.
Variable All (N=144) Males (N=83) Females (N=61)
Age (years)
Median (IQR) 62 (54-68) 62 (56-68) 59 (52-67.5)
Sleep Hygiene score
Median (IQR) 1.5 (1.18-1.90) 1.36 (1.13-1.81) 1.68 (1.31-2)
Pittsburgh Sleep Quality Index (PSQI)
Median (IQR) 6 (4-9) 5 (4-8) 6 (4-10)
PSQI≤5 (percentage, frequency) 67, 46.5% 46, 55.4% 21, 34.4%
PSQI>5 (percentage, frequency) 77, 53.5% 37, 44.6% 40, 65.6%
Table 2. Distribution of social, clinical and therapeutic characteristics of the enrolled patients.
Table 2. Distribution of social, clinical and therapeutic characteristics of the enrolled patients.
Variable All (N=144) Males (N=83) Females (N=61)
Highest level of education (Frequency, Percentage)
Primary School Diploma 4, 2.8% 3, 3.6% 1, 1.6%
Middle School Diploma 49, 34% 29, 34.9% 20, 32.8%
High School Diploma 62, 43.1% 36, 43.3% 26, 42.6%
Degree 28, 19.4% 14, 16.9% 14, 23%
Marital Status (Frequency, Percentage)
Married - Cohabiting 106, 73.6% 64, 77.1% 42, 68.9%
Separated – Divorced 17, 11.8% 10, 12% 7, 11.5%
Unmarried Maiden 12, 8.3% 7, 8.4% 5, 8.3%
Widow 8, 5.6% 1, 1.2% 7, 11.5%
Tumour Localization (Frequency, Percentage)
Lungs 6, 4.2% 4, 4.8% 2, 3.3%
Intestine 92, 63.9% 51, 61.4% 41, 67.2%
Stomach, Esophagus 27, 18.8% 19, 22.9% 8, 13.1%
Liver And Biliary Tract 5, 3.5% 2, 2.4% 3, 4.9%
Pancreas 13, 9% 8, 9.6% 5, 8.2%
Genitourinary Tract 1, 0.7% 0 1, 1.6%
Chemotherapy Administration (Frequency, Percentage)
Intravenous 144, 100% 83, 100% 61, 100%
Oral 23, 16% 15, 18.1% 8, 13.1%
Central Venous Catheter (Frequency, Percentage)
Present 143, 99.1% 82, 98.8% 61, 100%
Stoma (Frequency, Percentage)
Present 16, 11.1% 11, 13.3% 5, 8.2%
Nutrition (Frequency, Percentage)
Oral 141, 97.9% 80, 96.4% 59, 96.7%
Parenteral 3, 2.1% 2, 2.4% 1, 1.6%
Pain Sensation (Frequency, Percentage)
Present 32, 22.2% 15, 18.1% 17, 27.9%
Pain Relievers (Frequency, Percentage)
Paracetamol 20, 13.9% 10, 12% 10, 6.4%
Non-Steroidal Anti-Inflammatories 4, 2.8% 2, 2.4% 2, 3.3%
Opioids 11, 7.6% 6, 7.2% 5, 8.2%
Concomitant Pathologies (Frequency, Percentage)
Cardiovascular Diseases 48, 33.3% 27, 32.5% 21, 34.4%
Diabetes 15, 10.4% 12, 14.5% 3, 4.9%
Endocrine Disorders 9, 6.3% 2, 2.4% 7, 11.5%
Psychiatric Disorders 6, 4.2% 2, 2.4% 4, 6.6%
Arthritis, Arthrosis, Osteoporosis, Rheumatic Disorders 4, 2.8% 1, 1.2% 3, 4.9%
Gastric Disorders 3, 2.1% 1, 1.2% 2, 3.3%
Intestinal Disorders 1, 0.7% 1, 1.1% 0
Genitourinary Disorders 2, 1.4% 2, 2.4% 0
Neurological Disorders 3, 2.1% 3, 3.6% 0
Respiratory Disorders 0 0 0
Concomitant Therapies (Frequency, Percentage)
Corticosteroids 68, 47.2% 32, 38.6% 36, 59%
Antiemetics 67, 46.5% 35, 42.2% 32, 52.5%
Drugs For Cardiovascular Diseases 56, 38.9% 36, 43.4% 20, 32.8%
Antidepressants 7, 4.9% 2, 2.4% 5, 8.2%
Benzodiazepines 7, 4.9% 4, 4.8% 3, 4.9%
Drugs For Thyroid Diseases 9, 6.3% 2, 2.4% 7, 11.5%
Insulin And Oral Hypoglycemics 13, 9% 10, 12% 3, 4.9%
Antihistamines 8, 5.6% 6, 7.2% 2, 3.3%
Antipsychotics/Mood Stabilizers 0 0 0
Antiepileptics/Anticonvulsants 1, 0.7% 1, 1.2% 0
Previous Difficulty Sleeping (Frequency, Percentage)
Yes 23, 16% 8, 9.6% 15, 24.6%
Treatment For Difficulty Sleeping (Frequency, Percentage)
Phytotherapeutics 2, 1.4% 1, 1.2% 1, 1.6%
Melatonin 1, 0.7% 0 1, 1.6%
Chamomile And Herbal Teas 4, 2.8% 3, 3.6% 1, 1.6%
Drugs 10, 6.9% 3, 3.6% 7, 11.5%
Stress/Worries/Anxiety (Frequency, Percentage)
Yes 18, 12.5% 11, 13.25% 7, 11.48%
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated